newsfilter
← Latest News
GlobeNewswire·

Small Pharma Reports Fiscal First Quarter 2024 Highlights

• Last patient dosed in SPL026-SSRI drug interaction study with data readout anticipated in Q3 2023 • Potential for an expedited route to an international, multi-site Phase II study with SPL028 in 2024, based on